<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005029.pub2" GROUP_ID="MS" ID="384304022615170809" MERGED_FROM="" MODIFIED="2008-09-22 11:09:56 +0200" MODIFIED_BY="Liliana Coco" REVIEW_NO="1.5" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-09-22 11:02:11 +0200" MODIFIED_BY="Liliana Coco">
<TITLE>Treatment for ataxia in multiple sclerosis</TITLE>
<CONTACT>
<PERSON ID="9171831282E26AA201650CEA896F552A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roger</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Mills</LAST_NAME>
<SUFFIX/>
<POSITION>Research Registrar</POSITION>
<EMAIL_1>rjm@crazydiamond.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Trials Unit</DEPARTMENT>
<ORGANISATION>The Walton Centre for Neurology and Neurosurgery</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44-0151-529 5666</PHONE_1>
<PHONE_2/>
<FAX_1>+44-0151-529 5504</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-09-22 11:02:11 +0200" MODIFIED_BY="Liliana Coco">
<PERSON ID="9171831282E26AA201650CEA896F552A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roger</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Mills</LAST_NAME>
<SUFFIX/>
<POSITION>Research Registrar</POSITION>
<EMAIL_1>rjm@crazydiamond.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Trials Unit</DEPARTMENT>
<ORGANISATION>The Walton Centre for Neurology and Neurosurgery</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44-0151-529 5666</PHONE_1>
<PHONE_2/>
<FAX_1>+44-0151-529 5504</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="C1A2D12782E26AA20158075797F4A079" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Leesien</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Yap</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow</POSITION>
<EMAIL_1>leesien@tiscali.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurosciences</DEPARTMENT>
<ORGANISATION>The Walton Centre for Neurology and Neurosurgery</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>0151 529 5711</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14882" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carolyn</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Young</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Neurologist</POSITION>
<EMAIL_1>Carolyn.Young@thewaltoncentre.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Walton Centre for Neurology and Neurosurgery</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44-0151- 529 5711</PHONE_1>
<PHONE_2>+44-0151 529 5512</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-16 10:49:20 +0200" MODIFIED_BY="Liliana Coco">
<UP_TO_DATE>
<DATE DAY="27" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="6" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="8" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="28" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-28 09:53:27 +0200" MODIFIED_BY="Liliana Coco"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-22 11:05:31 +0200" MODIFIED_BY="Liliana Coco">
<SUMMARY MODIFIED="2008-08-28 09:58:13 +0200" MODIFIED_BY="Liliana Coco">
<TITLE MODIFIED="2008-08-28 09:58:13 +0200" MODIFIED_BY="Liliana Coco">The use of different treatment for incoordination of limb movement (ataxia) or tremor in people with multiple sclerosis</TITLE>
<SUMMARY_BODY>
<P>MS is a chronic disease of the central nervous system which typically affects both young and middle aged adults. It can result in many different symptoms including ataxia.</P>
<P>In order to help these symptoms, several different treatments, such as physiotherapy, neurosurgery, and oral medications containing cannabis extract, isoniazid or baclofen have been used. The authors conducted a search of the medical literature and found that only 10 out of 59 studies met the criteria of minimum methodological quality necessary for inclusion in this review. These studies represented a total of 172 MS patients with ataxia. This review has found that there is not enough evidence to suggest that any treatment (drugs, physiotherapy or neurosurgery) provides sustained improvement in ataxia or tremor. More research is required.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-09-22 11:02:42 +0200" MODIFIED_BY="Liliana Coco">
<ABS_BACKGROUND>
<P>Disabling tremor or ataxia is common in multiple sclerosis (MS) and up to 80% of patients experience tremor or ataxia at some point during their disease. A variety of treatments are available, ranging from pharmacotherapy or stereotactic neurosurgery to neurorehabilitation.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the efficacy and tolerability of both pharmacological and non-pharmacologic treatments of ataxia in patients with MS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-09-22 11:02:42 +0200" MODIFIED_BY="Liliana Coco">
<P>The following electronic resources were searched: Cochrane MS Group trials register (June 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2006), MEDLINE (January 1966 to June 2006), EMBASE (Jan 1988 to June 2006) and the National Health Service National Research Register (NRR) including the Medical Research Council Clinical Trials Directory (Issue 2, 2006). Manual searches of bibliographies of relevant articles, pertinent medical and neurology journals and abstract books of major neurology and MS conferences (2001-2006) were also performed. Direct communication with experts and drug companies was sought.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Blinded, randomised trials which were either placebo-controlled or which compared two or more treatments were included. Trials testing pharmacological agents must have had both participant and assessor blinding. Trials testing surgical interventions or effects of physiotherapy, where participants could not have been blinded to the treatment, must have had independent assessors who were blinded to the treatment. Cross-over trials were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Three independent reviewers extracted data and the findings of the trials were summarised. A meta-analysis was not performed due to the inadequacy of outcome measures and methodological problems with the studies reviewed. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Ten randomised controlled trials met the inclusion criteria. Six placebo-controlled studies (pharmacotherapy) and four comparative studies (one stereotactic neurosurgery and three neurorehabilitation) were reviewed. No standardised outcome measures were used across the studies. In general, pharmacotherapies were unrewarding and data on neurosurgery or rehabilitation is insufficient to lead to a change in practice.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-08-28 09:58:52 +0200" MODIFIED_BY="Liliana Coco">
<P>The absolute and comparative efficacy and tolerability of pharmacotherapies to treat ataxia in MS are poorly documented and no recommendations can be made to guide prescribing. Although studies on neurosurgery and neurorehabilitation showed promising results, the absolute indications for treating with those methods cannot be developed. Standardised, well validated measures of ataxia and tremor need to be developed and employed in larger randomised controlled trials with careful blinding.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-22 11:05:31 +0200" MODIFIED_BY="Liliana Coco">
<BACKGROUND>
<P>The word ataxia (from the Greek) literally means disorder or confusion (<LINK REF="REF-Simpson-1990" TYPE="REFERENCE">Simpson 1990</LINK>). Clinically, it is used to describe various abnormalities that can occur in the execution of voluntary movement; including incoordination, dysmetria, dysdiadochokinesis and tremor. It results from lesions in the cerebellum and its connections (<LINK REF="REF-Ghez-2000" TYPE="REFERENCE">Ghez 2000</LINK>).</P>
<P>The incidence of ataxia in MS is high with about 80% of patients experiencing symptoms at some point during their disease (<LINK REF="REF-Swingler-1992" TYPE="REFERENCE">Swingler 1992</LINK>). The multiplicity of lesions, in MS, make histological correlation with clinical features difficult (<LINK REF="REF-Alusi-1999" TYPE="REFERENCE">Alusi 1999</LINK>, <LINK REF="REF-Alusi-2001a" TYPE="REFERENCE">Alusi 2001a</LINK>), however, in MS patients with chronic cerebellar ataxia, disability has been shown to correlate with the number of infratentorial T1 hypointense lesions seen on MR imaging (<LINK REF="REF-Hickman-2001" TYPE="REFERENCE">Hickman 2001</LINK>). The influence of sensory afferents on cerebellar dysfunction has been demonstrated in MS, in keeping with other cerebellar disorders (<LINK REF="REF-Quintern-1999" TYPE="REFERENCE">Quintern 1999</LINK>).</P>
<P>There are several ways of assessing ataxia and tremor ranging from simple functional tests such as timed walks, target board tests, writing and drawing tests and measuring the volume of water spilt from a cup (<LINK REF="REF-Alusi-1999" TYPE="REFERENCE">Alusi 1999</LINK>, <LINK REF="REF-Alusi-2003" TYPE="REFERENCE">Alusi 2003</LINK>, <LINK REF="REF-Erasmus-2001" TYPE="REFERENCE">Erasmus 2001</LINK>); to rating scales such as the Kurtzke functional system (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>) and the Fahn tremor rating [<LINK REF="REF-Fahn-1988" TYPE="REFERENCE">Fahn 1988</LINK>]; to more complex kinematic analyses using three dimensional, infrared or video tracking of reflective markers placed at joints with or without accompanying electromyography (<LINK REF="REF-Quintern-1999" TYPE="REFERENCE">Quintern 1999</LINK>, <LINK REF="REF-Murray-1999" TYPE="REFERENCE">Murray 1999</LINK>).</P>
<P>This review evaluates the effectiveness and tolerability of treatments for ataxia in patients with MS.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the efficacy and tolerability of both pharmacological and non-pharmacologic treatments of ataxia and tremor in patients with MS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-22 11:05:31 +0200" MODIFIED_BY="Liliana Coco">
<SELECTION_CRITERIA MODIFIED="2008-08-28 10:00:28 +0200" MODIFIED_BY="Liliana Coco">
<CRIT_STUDIES>
<P>Blinded, randomised trials (RCTs) which either were placebo-controlled or which compared two or more treatments were included. Quasi-randomised or unrandomised trials were excluded. Trials testing pharmacological agents must have had both participant and assessor blinding. Trials testing surgical interventions or effects of physiotherapy, where participants could not be blinded to the treatment, must, at least, have had independent assessors who were blinded to the treatment. Cross-over trials were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients, of any age and either sex, with MS (satisfying either the Poser (<LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>) or McDonald (<LINK REF="REF-McDonald-2001" TYPE="REFERENCE">McDonald 2001</LINK>) criteria) of any course type, were included. The patients must have had symptoms or signs of ataxia, the presence of action tremor without other features of ataxia also qualified.</P>
<P>Patients within thirty days of a relapse or within thirty days of receiving corticosteroids were excluded (studies where this was not explicitly stated were included). Studies including patients with other diagnoses were excluded unless individual data for the MS patients could be obtained either from the published results or through contact with the authors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Use of a pharmacological agent in at least one arm of the study for at least one week. Surgical interventions, such as deep brain stimulation, or orthoses, such as splints or weights, or physiotherapy were considered if they were amenable to assessor blinding.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-28 10:00:28 +0200" MODIFIED_BY="Liliana Coco">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-08-28 10:00:17 +0200" MODIFIED_BY="Liliana Coco">
<P>Efficacy: whether the intervention produces a change in severity of ataxia as measured by any validated method.<BR/>Safety: the incidence of adverse, or serious adverse, events.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-08-28 10:00:24 +0200" MODIFIED_BY="Liliana Coco">
<P>Efficacy: change in activity limitation (disability) ratings or in quality of life scores. Duration of treatment efficacy.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-22 11:05:31 +0200" MODIFIED_BY="Liliana Coco">
<ELECTRONIC_SEARCHES MODIFIED="2008-09-22 11:05:31 +0200" MODIFIED_BY="Liliana Coco">
<P>1) Electronic searches of: i) Cochrane MS Group Trials Register (June 2006), ii) The Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 2, 2006) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), iii) MEDLINE (1966-June 2006),(<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) iv) EMBASE (1988-June 2006) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-08-28 10:01:51 +0200" MODIFIED_BY="Liliana Coco">
<P>2) Reference lists from published reviews on symptom control in multiple sclerosis and identified RCTs.</P>
<P>3) Personal communication with first authors of relevant trials or reviews, and other multiple sclerosis experts.</P>
<P>4) Drug manufacturers for drugs identified in relevant RCTs.</P>
<P>5) National Health Service National Research Register (NRR) including the Medical Research Council Clinical Trials Directory.</P>
<P>6) Manual searches of pertinent medical and neurology journals (Neurology, Journal of Neurology; Multiple Sclerosis, Clinical Rehabilitation; Neurosurgery; Journal of Neurosurgery; Journal of Neurology; Neurosurgery and Psychiatry) and abstract books (2001-2006) of ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis); EFNS (European Federation of Neurological Societies); ENS (European Neurological Society); ABN (Association of British Neurologists); AAN (American Academy of Neurology) and ANA (American Neurological Association).</P>
<P>Unpublished trials were identified using strategies 3), 4), 5) and 6).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Study selection and data extraction</B>
<BR/>Titles and abstracts of papers identified using the above strategies were assessed by three independent reviewers (RJM, CAY and LY); full text versions were viewed where possible. Agreement on which studies meet the inclusion criteria was reached by consensus.</P>
<P>
<B>Assessment of methodological quality</B>
<BR/>The methodological quality of the studies was assessed, according to the guidelines in the Cochrane Reviewer's Handbook (<LINK REF="REF-Clarke-2003" TYPE="REFERENCE">Clarke 2003</LINK>), for: selection bias, performance bias, attrition bias and detection bias. A summary rating of A (low bias), B (moderate bias) or C (high bias) was given to each study independently by each reviewer. Differences in assessment were reached by consensus. Studies with high risk of bias were discarded. Patient and study characteristics and outcome data were abstracted by the three reviewers.</P>
<P>
<B>Analysis</B>
<BR/>Meta analysis was not performed given the diversity of interventions and outcome measures. A description of the results for each individual study is given.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Ten, of 56 identified studies, met the inclusion criteria.</P>
<P>
<B>(1) Isoniazid and pyridoxine versus placebo</B>
</P>
<P>Two crossover studies (<LINK REF="STD-Bozek-1987" TYPE="STUDY">Bozek 1987</LINK>; <LINK REF="STD-Hallett-1985" TYPE="STUDY">Hallett 1985</LINK>) have been reviewed. In both studies, the treatment arms were of four weeks duration with a one week washout period in Hallet 1985, before crossover, and no washout period in <LINK REF="STD-Bozek-1987" TYPE="STUDY">Bozek 1987</LINK>. Different doses of isoniazid were used: <LINK REF="STD-Hallett-1985" TYPE="STUDY">Hallett 1985</LINK> started with a minimal dose of 300mg once per day, increased to twice a day during the second week, three times a day in the third week and four times a day in the fourth week. In Bosek 1987 the acetylator phenotype of the patient (based on the ability to acetylate a standard 11mg/kg dose of sulfamethazine) determined the daily dosage of isoniazid administered. Slow acetylators received Isoniazid 12mg/kg per day and rapid acetylators 20mg/kg per day.<BR/> <BR/>
<B>(2) Cannabis based medicine versus placebo</B>
</P>
<P>One parallel (<LINK REF="STD-Wade-2004" TYPE="STUDY">Wade 2004</LINK>) and two crossover studies (<LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK>, <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK>) have been reviewed. <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> compared oral preparations of dronabinol, cannabis sativa plant extract and placebo in a two fold cross over trial. <LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK> used oral Cannador in a crossover study and <LINK REF="STD-Wade-2004" TYPE="STUDY">Wade 2004</LINK> used cannabis based medicinal extract (Sativex), administered by sublingual spray, in a parallel group study.</P>
<P>
<B>(3) Baclofen versus placebo</B>
</P>
<P>One crossover study using baclofen has been reviewed (<LINK REF="STD-Orsnes-2000" TYPE="STUDY">Orsnes 2000</LINK>). The starting dose was 5mg three times daily and dose escalation by 5mg every 3 days to 15mg 3 times daily or the maximum tolerance dosage with no side effects experienced. After 11 days on this dosage, measurements were performed and the treatment was tapered over about one week. There was a two week washout period before crossing to the alternative treatment using identical regime. </P>
<P>
<B>(4) Thalamotomy versus deep brain stimulation (DBS)</B>
</P>
<P>One comparative study has been reviewed (<LINK REF="STD-Schuurman-2000" TYPE="STUDY">Schuurman 2000</LINK>). Up to two years follow up assessments were reported. Patients were randomised to either thalamic stimulation or thalamotomy in a single blinded randomised controlled trial. Of the 68 trial patients 10 had MS and were randomised equally between the two treatments.</P>
<P>
<B>(5) Comparative physiotherapy /neurorehabilitation studies</B>
</P>
<P>Three different types of comparative studies of variable durations have been reviewed. <LINK REF="STD-Armutlu-2001" TYPE="STUDY">Armutlu 2001</LINK> compared the effects of neuromuscular rehabilitation with and without the addition of Johnstone pressure splints. <LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK> compared hospital physiotherapy with home physiotherapy and no treatment. <LINK REF="STD-Lord-1998" TYPE="STUDY">Lord 1998</LINK> described a parallel study of facilitation physiotherapy (impairment based) versus task orientated physiotherapy (disability based). </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>(1) Isoniazid and pyridoxine versus placebo</B>
</P>
<P>
<LINK REF="STD-Bozek-1987" TYPE="STUDY">Bozek 1987</LINK> studied 10 MS patients; disease stability in the preceding month was not reported. Patients, treating physicians and assessors were blinded but there was a risk of unblinding of treating physician by liver function test monitoring. There was moderate attrition bias with 20% dropout rate due to side effects or non efficacy.</P>
<P>
<LINK REF="STD-Hallett-1985" TYPE="STUDY">Hallett 1985</LINK> recruited 7 MS patients with postural cerebellar tremor; disease stability in the preceding month was not reported. Patients, treating physician and assessor were blinded. There was moderate attrition bias with 14% dropout rate plus loss of quantitative data in another 14%.</P>
<P>In both studies the method of allocation concealment was unclear. Both studies used videotaped tremor ratings and tremograms as outcome measures. </P>
<P>
<B>(2) Cannabis based medicine versus placebo</B>
</P>
<P>
<LINK REF="STD-Wade-2004" TYPE="STUDY">Wade 2004</LINK> involved three centres across the UK with clearly specified patient eligibility criteria. 160 patients with clinically confirmed MS, which had been stable for four weeks, were recruited. Each had one of five target symptoms: spasticity, spasms, bladder problems, tremor or pain and were willing to abstain from alternative cannabinoid use for 7 days prior to screening and throughout the study. Only 13 patients had tremor as their primary symptom. All 13 tremor patients completed the study. Patients, treating physicians and assessors were blinded but patient blinding was compromised by dose dependent side effects; an unblinding questionnaire was not administered.</P>
<P>
<LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK> included 14 patients with clinically definite MS with visible upper limb tremor; disease stability in the preceding month was not reported. Thirteen patients completed the study. Patients, treating physicians and assessors were blinded but both patient and treating physician blinding was compromised since doses were titrated to side effects. Nine out of 14 patients were correct in an unblinding questionnaire.</P>
<P>
<LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> included 16 patients with clinically confirmed MS with spasticity, tremor being a secondary study aim. Patients with Ashworth (<LINK REF="REF-Ashworth-1964" TYPE="REFERENCE">Ashworth 1964</LINK>) spasticity score of at least 2 in at least one limb were included and those who had used cannabinoids in the two months preceding study entry were excluded. All patients completed the study. Patients, treating physicians and assessors were blinded, but patient and treating physician unblinding was noted (exact percentage not given).</P>
<P>The methods of allocation concealment were unclear in <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK>. <LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK> used a computer generated list of numbers held by the dispensing pharmacy. In <LINK REF="STD-Wade-2004" TYPE="STUDY">Wade 2004</LINK>, randomisation was conducted using permuted blocks of size 4, stratified by nominated primary symptom and centre. The pharmacist at each centre was provided with a randomised scheme for each primary symptom and assigned the treatments in sequential patient number order from the appropriate randomisation list. Outcome measures varied across the studies. <LINK REF="STD-Wade-2004" TYPE="STUDY">Wade 2004</LINK> used a 100mm visual analogue scale (VAS) for tremor (anchors not given), a tremor activities of daily living (ADL) questionnaire and a nine hole peg test (9HPT). <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> used the 9HPT and a daily VAS as tremor outcome measures. <LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK> used spirography, 9HPT, accelerometry and videotaped tremor assessments.</P>
<P>
<B>(3) Baclofen versus placebo</B>
</P>
<P>Fourteen patients with clinically definite MS and stable disease for at least one month were included in the <LINK REF="STD-Orsnes-2000" TYPE="STUDY">Orsnes 2000</LINK> study. All patients had moderate functional deficits and were able to walk unaided and without support for at least 3 minutes. Antispasticity agents were withheld for one week prior to entry to the study and no medication that could affect spasticity was allowed during the study period; no alcohol during the last 12 hours before the tests was permitted. All patients completed the study. Both patients and treating physicians were blinded. It was unclear whether an independent assessor was used.</P>
<P>The method of allocation concealment was unclear. The ataxia outcome measure was a measurement of postural sway generated by computer from data from a force plate.</P>
<P>
<B>(4) Thalamotomy versus deep brain stimulation (DBS)</B>
</P>
<P>
<LINK REF="STD-Schuurman-2000" TYPE="STUDY">Schuurman 2000</LINK> included 68 patients with severe unilateral or bilateral tremor of the arms refractory to at least 1 year of pharmacotherapy. There were 10 MS patients. Patients were excluded if they were younger than 18 years of age; had cognitive dysfunction, had concomitant medical disease with poor pre-morbid state, advanced cerebral atrophy on computed tomography or had previously undergone thalamotomy. Patients and the surgeons were necessarily unblinded to the treatment but assessment of tremor was made by a blinded neurologist. The thalamic stimulation patients received more frequent medical contact.</P>
<P>Randomisation was performed according to a computer generated code, with adjustment for the cause and extent of tremor (unilateral vs bilateral). Ataxia outcomes were made at time points of up to six months post procedure and included assessment of videotaped tremor, a tremor scale and patient's opinion of the surgical outcome.</P>
<P>
<B>(5) Comparative physiotherapy/neurorehabilitation studies</B>
</P>
<P>
<LINK REF="STD-Armutlu-2001" TYPE="STUDY">Armutlu 2001</LINK> included 26 MS patients with either secondary progressive or primary progressive MS who had prominent ataxia with slight muscle weakness and could walk unaided. Corticosteroids were discontinued at least 1 month before the start of the study. All patients completed the study. Patients and treating physiotherapists were unblinded to the treatment; two blinded physiotherapists were used for assessment.</P>
<P>
<LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK> included 42 patients with definite or probable multiple sclerosis who complained of difficulties with walking. Patients were required to be at least 18 years old, able to walk for 5 minutes with or without aid, and be relapse free. There was a 7% dropout rate. Patients and treating physiotherapists were unblinded to the treatment; a blinded physiotherapist was used for assessments.</P>
<P>
<LINK REF="STD-Lord-1998" TYPE="STUDY">Lord 1998</LINK> included 23 patients with MS referred to a specialist rehabilitation service and who were able to walk 10 m with or without supervision and who had been relapse free in the three months prior to entry to study. There was a 13% dropout rate due to relapse. Patients and treating physiotherapists were unblinded to the treatment; a blinded physiotherapist was used for assessments. However, patients were unlikely to have had strong preference for either form of treatment.</P>
<P>Randomisation was performed in both <LINK REF="STD-Lord-1998" TYPE="STUDY">Lord 1998</LINK> and <LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK> using sealed envelopes. The method of allocation concealment in <LINK REF="STD-Armutlu-2001" TYPE="STUDY">Armutlu 2001</LINK> was unclear. All the studies used various clinical scoring systems of balance, gait and ataxia.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>A meta-analysis was not attempted in view of the different inclusion criteria for each study and the variety of the outcome measures used.</P>
<P>
<B>(1) Isoniazid and pyridoxine versus placebo</B>
</P>
<P>In <LINK REF="STD-Bozek-1987" TYPE="STUDY">Bozek 1987</LINK>, a patient was withdrawn due to a probable hypersensitivity reaction. This resolved when isoniazid was discontinued. <LINK REF="STD-Hallett-1985" TYPE="STUDY">Hallett 1985</LINK> reported no side effects from isoniazid.</P>
<P>
<LINK REF="STD-Bozek-1987" TYPE="STUDY">Bozek 1987</LINK> reported minimal clinical improvement on videotaped assessment (the level of statistical significance was not given), there was no significant change in tremograms. <LINK REF="STD-Hallett-1985" TYPE="STUDY">Hallett 1985</LINK> reported that 4 out of 7 patients were 'better' on subjective assessment, there were no significant changes in accelerometry.</P>
<P>Neither study made any assessments beyond the duration of the study drug administration. There were no changes in disability scores (disability status scores <LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>).</P>
<P>
<B>(2) Cannabis based medicine versus placebo</B>
</P>
<P>Across the studies, cannabis was well tolerated. Common side effects were mild dizziness, intoxication and drowsiness.</P>
<P>
<LINK REF="STD-Wade-2004" TYPE="STUDY">Wade 2004</LINK> reported no change in VAS and 9HPT scores. <LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK> found that all changes in ataxia outcomes were non significant apart from worsening in finger tapping speed. <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> found that 9HPT scores were significantly worse with dronabinol but were no different with plant extract.</P>
<P>Disability outcomes were largely unchanged although <LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK> found that plant extract caused significant worsening of the Multiple Sclerosis Functional Composite (MSFC) whereas dronabinol led to improvement in the mental health and quality of life domains of the Short Form-36 (SF-36). None of the studies made any assessments beyond the duration of the study drug administration.</P>
<P>The conclusion derived from all three studies was that cannabis based medicine resulted in no significant improvement in tremor. </P>
<P>
<B>(3) Baclofen versus placebo</B>
</P>
<P>
<LINK REF="STD-Orsnes-2000" TYPE="STUDY">Orsnes 2000</LINK> noted that 9 out of 14 patients reported side effects from baclofen, such as fatigue and dizziness. These effects were transient and mild. </P>
<P>There was no statistically significant change in postural stability or the other outcomes of general disability. No assessments were made beyond the duration of the study drug administration.</P>
<P>
<B>(4) Thalamotomy versus deep brain stimulation (DBS)</B>
</P>
<P>There were adverse effects in both treatment groups of gait disturbance, dysarthria and, paradoxically, arm ataxia. There was one surgery related death due to intracerebral heamorrahage although this was not in an MS patient. Some of these adverse symptoms were persistent at 6 months.</P>
<P>Tremor was abolished by both thalamotomy and thalamic stimulation in all patients immediately post surgery. However, at 6 months, tremor had returned in almost all the MS patients, albeit of less severity than pre operative levels. For the MS patients, there was no change in general disability scores.</P>
<P>
<B>(5) Comparative physiotherapy /neurorehabilitation studies</B>
</P>
<P>In all three studies, there were no adverse events reported.</P>
<P>
<LINK REF="STD-Armutlu-2001" TYPE="STUDY">Armutlu 2001</LINK> reported improvements in single limb stance time of between 10 and 30 seconds plus step width of about 3cm, after physiotherapy. The addition of Johnstone pressure splints gave no extra advantage. <LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK> found that 16 sessions of physiotherapy, in either hospital or at home, improved balance time by about 5 seconds. Hospital treatment similarly gave very small improvement in time taken to complete a 9HPT (mean values of 190 seconds vs. 207 seconds) whereas home therapy did not. <LINK REF="STD-Lord-1998" TYPE="STUDY">Lord 1998</LINK> found significant improvements in Berg balance tests with both forms of physiotherapy.</P>
<P>Both <LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK> and <LINK REF="STD-Lord-1998" TYPE="STUDY">Lord 1998</LINK> found small improvements of about 1.5 units in the Rivermead mobility index. <LINK REF="STD-Armutlu-2001" TYPE="STUDY">Armutlu 2001</LINK> found improvement in the EDSS (Expanded disability status scale <LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>) of 0.5 units. Only <LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK> made assessments beyond the treatment duration; it was found that scores had returned to pre treatment levels after two months.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Of the 56 studies conducted over the past 25 years, only ten satisfied the criteria of minimum methodological quality necessary for inclusion in this review. These trials represented the study of a total of 172 MS patients with ataxia or tremor. Several studies had very small sample sizes (n&lt;20). All had a moderate risk of bias, mainly due to inadequate blinding or subject attrition. Nearly all the interventions resulted in little or no lasting change in ataxia.</P>
<P>
<B>Blinding</B>
<BR/>Blinding of both patient and clinician/assessor is the central tenet in eliminating performance bias; it is crucial if self rating outcome measures are used. However, despite best efforts in trial design, there are some interventions which are very difficult to blind. Pharmacological agents with inevitable side effects, such as intoxication, make the use of agents such as alcohol (<LINK REF="STD-Koller-1984a" TYPE="STUDY">Koller 1984a</LINK>, <LINK REF="STD-Koller-1984b" TYPE="STUDY">Koller 1984b</LINK>) or cannabinoids open to unintentional unblinding (<LINK REF="STD-Zajicek-2003" TYPE="STUDY">Zajicek 2003</LINK>). Surgical procedures, if compared to no intervention, cannot be double blinded and even sham operations only result in single blinding. Similarly, physiotherapy vs. no treatment is impossible to blind; however, comparative studies of physiotherapy may approximate to patient blinding.</P>
<P>
<B>Outcomes</B>
<BR/>There is no fully validated tremor outcome measure specific for MS and so it was unsurprising that several different outcome measures were used between the studies. There were various subjective clinical assessments of videotaped performance, accelerometry from wrist worn devices, surface electromyographic (EMG) recordings, self rating scales, time to complete a 9HPT, balance time and analysis of stance on a forceplate.</P>
<P>Subjective clinical assessments of tremor, based on videotaped performance, are reproducible if an individual rater is used. However, they can suffer from problems with interrater reliability because severity is assessed by reference to the clinician's own experience and opinion rather than to some common standard (<LINK REF="REF-Hooper-1998" TYPE="REFERENCE">Hooper 1998</LINK>). In addition, for assessment of gait, videotaped evaluation does not correlate well with 'live' evaluation (<LINK REF="REF-Wiles-2003" TYPE="REFERENCE">Wiles 2003</LINK>). The sensitivity to change of this type of assessment is not known.</P>
<P>The use of accelermoters, EMG and forceplates have the advantage of providing objective data, although some interpretation may still rely on subjective analysis of traces produced (<LINK REF="STD-Hallett-1985" TYPE="STUDY">Hallett 1985</LINK>). There is no work on what would represent minimum clinically detectable changes e.g. a 10% reduction in peak tremor velocity may be statistically significant but may not be noticeable by the patient or clinician. Even noticeable changes may not, of course, result in any benefit in the subject being able to perform a particular task. </P>
<P>Although tests such as 9HPT have been well validated in MS as an outcome of upper limb/prehensile function, particularly as part of the MSFC (<LINK REF="REF-Rudick-2002" TYPE="REFERENCE">Rudick 2002</LINK>), as a pure measure of ataxia it could be confounded by weakness, spasticity or visual impairment.</P>
<P>
<B>Study size</B>
<BR/>Sample size calculations rely on knowledge of the performance of the outcome measures used. Therefore, determination of sample size was problematic for the studies in this review because of the lack of validated outcome measures. Only three studies attempted formal power calculations either based on limited previous experience (<LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK>, <LINK REF="STD-Wade-2004" TYPE="STUDY">Wade 2004</LINK>) or by looking for large (50%) changes in scores (<LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK>). Many of the older pharmacotherapy studies were probably underpowered and <LINK REF="STD-Orsnes-2000" TYPE="STUDY">Orsnes 2000</LINK> acknowledged that small sample size may have confounded his results</P>
<P>Comparative studies require greater numbers than placebo (or no treatment) controlled studies, in to order to demonstrate differences between treatments and this may partly account for the studies by <LINK REF="STD-Armutlu-2001" TYPE="STUDY">Armutlu 2001</LINK> and <LINK REF="STD-Lord-1998" TYPE="STUDY">Lord 1998</LINK> failing to detect such between treatment effects.</P>
<P>
<B>Some notable exclusions</B>
<BR/>There were two studies of intravenous treatments of 5HT3 receptor antagonists (<LINK REF="STD-Rice-1997" TYPE="STUDY">Rice 1997</LINK>, <LINK REF="STD-Monaca_x002d_Charley-2003" TYPE="STUDY">Monaca-Charley 2003</LINK>) that were excluded because treatment was limited to a single dose. It was not clear why longer treatment regimes were not used; it is difficult to make any recommendations for treatment of chronic symptoms from a single dose study. <LINK REF="STD-Rice-1997" TYPE="STUDY">Rice 1997</LINK> promised a study of an oral 5HT3 receptor antagonist but this does not appear to have been published. Attempts at contacting the authors, via the contact details given in publications, were unsuccessful and so it was not possible to determine whether this trial had been undertaken. The CAMS study (<LINK REF="STD-Zajicek-2003" TYPE="STUDY">Zajicek 2003</LINK>) was a large study of tetrahydrocannabinol given orally. Ataxia was only a self rated secondary outcome and, by the investigators' own admission, there was significant unblinding (66-71% of treating physicians and 71% of patients correctly identified active study drug, p&lt;0.001) due to side effects. It was therefore not included in the review.</P>
<P>
<B>Results</B>
<BR/>Many studies failed to show significant differences in primary outcome measures for pharmacotherapy vs placebo and indeed some showed deleterious effects (<LINK REF="STD-Killestein-2002" TYPE="STUDY">Killestein 2002</LINK>, <LINK REF="STD-Fox-2004" TYPE="STUDY">Fox 2004</LINK>) It is difficult to interpret this as true absence of effect. The combination of performance bias and attrition bias plus small sample sizes and deficiencies in outcome measures are likely to result in potentially sizeable confounds. When measured, there was little benefit seen in secondary outcomes of general disability scores or quality of life. Physiotherapy was safe and improved outcomes by small amounts, however, there was a suggestion that treatment effects would not be sustained (<LINK REF="STD-Wiles-2001" TYPE="STUDY">Wiles 2001</LINK>).</P>
<P>Surgical treatment showed good effect in the short term for those with severe symptoms and could even abolish tremor. However for MS, the tremor was likely to have returned by six months. There was no improvement in disability scores at six month follow up; there may have been unmasking of other cerebellar symptoms. As with many surgical procedures, case selection is important in determining outcome and so it may not be suitable, or desirable, for large groups of MS patients. There is a risk of serious adverse events.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>A large number of studies have attempted to assess the efficacy and tolerability of various pharmacological agents and non-pharmacological therapies and have been identified by this systematic review. Only about a fifth were of sufficient methodological quality to warrant being reviewed in greater detail. The variability in inclusion criteria for each study and the lack of standardised, sensitive and reliable assessment tools for tremor and ataxia made direct comparison of studies unfeasible. No firm recommendations to change practice can be drawn from this review.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a need for well designed RCTs focussing on ataxia in MS. Some pharmacotherapautic agents need to be reassessed in a more rigorous way; further agents need to be developed. Safety and efficacy of functional neurosurgery in MS needs further clarification in order to guide referral pathways for this potentially useful treatment.</P>
<P>All future studies need to be adequately powered but this cannot be done before a well validated, sensitive and, preferably, internationally agreed, outcome measure or assessment tool has been developed. Such a tool must be easily available and readily performed by both the patient and assessor. More comparative studies with larger study populations are also encouraged.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to thank Dr Tim Friede for his advice and statistical guidance on the protocol for this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Nil known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Link with editorial base - RJM<BR/>Review the correspondence - RJM<BR/>Draft the protocol - RJM, CAY, TF<BR/>Search for trials - LY, RJM, CAY,<BR/>Obtain copies of trials - RJM, LY<BR/>Select which trials to include - RJM, CAY, LY<BR/>Extract data from trials - RJM, CAY, LY<BR/>Enter data into Revman - RJM<BR/>Carry out the analysis - RJM, CAY, LY<BR/>Interpret the analysis - RJM, CAY, LY<BR/>Draft the final review - RJM, CAY, LY<BR/>Update the review - RJM, CAY, LY<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-01 09:27:01 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDIES MODIFIED="2008-09-01 09:27:01 +0200" MODIFIED_BY="Deirdre Beecher">
<INCLUDED_STUDIES MODIFIED="2008-09-01 09:26:01 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDY DATA_SOURCE="PUB" ID="STD-Armutlu-2001" MODIFIED="2008-09-01 09:26:01 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Armutlu 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-01 09:26:01 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armutlu K, Karabudak R, Nurlu G</AU>
<TI>Physiotherapy approaches to the treatment of ataxic multiple sclerosis: a pilot study</TI>
<SO>Neurorehabilitation and Neural Repair</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>203-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bozek-1987" MODIFIED="2008-08-29 12:15:08 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Bozek 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-08-29 12:15:08 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bozek CB, Kastrukoff LF, Wright JM, Perry TL, Larsen TA</AU>
<TI>A controlled trial of isoniazid therapy for action tremor in multiple sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1987</YR>
<VL>234</VL>
<NO>1</NO>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-2004" MODIFIED="2008-08-29 12:15:24 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Fox 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-29 12:15:24 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox P, Bain PG, Glickman S, Carroll C, Zajicek J</AU>
<TI>The effect of cannabis on tremor in patients with multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>7</NO>
<PG>1105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallett-1985" MODIFIED="2008-08-29 12:15:40 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Hallett 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-08-29 12:15:40 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallett M, Lindsey JW, Adelstein BD, Riley PO</AU>
<TI>Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclersosis</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>9</NO>
<PG>1374-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killestein-2002" MODIFIED="2008-08-29 12:16:10 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Killestein 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-29 12:16:10 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenan AC, Staats PG et al</AU>
<TI>Safety, tolerability, and afficacy of orally administered cannabinoids in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<NO>9</NO>
<PG>1404-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lord-1998" MODIFIED="2008-08-29 12:16:27 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Lord 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-29 12:16:27 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lord SE, Wade DT, Halligan PW</AU>
<TI>A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study</TI>
<SO>Clinical Rehabilitation</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>447-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orsnes-2000" MODIFIED="2008-08-29 12:16:58 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Orsnes 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-08-29 12:16:58 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orsenes GB, Sorenson PS, Larsen TK, Ravnborg M</AU>
<TI>Effect of baclofen on gait in spastic multiple sclersosis patients</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2000</YR>
<VL>101</VL>
<NO>4</NO>
<PG>244-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuurman-2000" MODIFIED="2008-08-29 12:17:38 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Schuurman 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-08-29 12:17:38 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, de Bie RM et al</AU>
<TI>A comparison of continuous thalamic stimulation and thalamotomy for supression of severe tremor</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>7</NO>
<PG>461-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wade-2004" MODIFIED="2008-08-29 12:17:59 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Wade 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-29 12:17:59 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wade DT, Makela P, Robson P, House H, Bateman C</AU>
<TI>Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients</TI>
<SO>Multiple Sclerosis</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>434-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiles-2001" MODIFIED="2008-08-29 12:18:27 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Wiles 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-29 12:18:27 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiles CM, Newcombe RG, Fuller KJ, Shaw S, Furnival-Doran J, Pickersgill TP et al</AU>
<TI>Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>2001</YR>
<VL>70</VL>
<NO>2</NO>
<PG>174-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-09-01 09:27:01 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-1991" MODIFIED="2008-08-29 12:19:27 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Aisen 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-08-29 12:19:27 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen ML, Holzer M, Rosen M, Dietz M, McDowell F</AU>
<TI>Glutethiamide treatment of disabling action tremor in patients with multiple sclesrosis and traumatic brain injury</TI>
<SO>Archives of Neurology</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>5</NO>
<PG>513-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alusi-2001b" MODIFIED="2008-08-29 12:19:49 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Alusi 2001b" YEAR="2001">
<REFERENCE MODIFIED="2008-08-29 12:19:49 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alusi SH, Aziz TZ, Glickman S, Jahanshahi M, Stein JF, Bain P.G</AU>
<TI>Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: a prospective case-controlled study</TI>
<SO>Brain</SO>
<YR>2001</YR>
<VL>124</VL>
<NO>8</NO>
<PG>1576-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakhos-2002" MODIFIED="2008-08-29 12:20:09 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Bakhos 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-29 12:20:09 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bakhos CT, Jabre MG, Habub KG, Chemaly R</AU>
<TI>Gabapentin in the treatment of tremor in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<PG>459</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benabid-1998" MODIFIED="2008-08-29 12:20:29 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Benabid 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-29 12:20:29 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benabid AL, Pollak P, Gao D, Hoffmann D, Limousin P, Gay E</AU>
<TI>Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1996</YR>
<VL>84</VL>
<NO>2</NO>
<PG>203-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berk-2002" MODIFIED="2008-08-29 12:20:53 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Berk 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-29 12:20:53 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berk C, Carr J, Sinden M, Martzke J, Honey CR</AU>
<TI>Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>4</NO>
<PG>815-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bittar-2005" MODIFIED="2008-08-29 12:21:17 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Bittar 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-29 12:21:17 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bittar R.G, Hyam J, Nandi D, Wang S, Liu X, Joint C et al</AU>
<TI>Thalamotomy versus thalamic stimulation for multiple sclerosis tremor</TI>
<SO>Journal of clinical neuroscience</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>6</NO>
<PG>638-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brice-1980" MODIFIED="2008-08-29 12:24:06 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Brice 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-08-29 12:24:06 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brice J, Mclellan L</AU>
<TI>Suppression of intention tremor by contingent deep-brain stimulation</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>315</VL>
<NO>8180</NO>
<PG>1221-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cardini-2000" MODIFIED="2008-08-29 12:24:25 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Cardini 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-08-29 12:24:25 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cardini RG, Crippa AC, Catteneo D</AU>
<TI>Update on multiple sclerosis rehabilitation</TI>
<SO>Journal of Neurovirology</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>suppl 2</NO>
<PG>179-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Critchley-1998" MODIFIED="2008-08-29 12:25:23 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Critchley 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-29 12:25:23 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Critchley GR, Richardson PL</AU>
<TI>VIM thalamotomy for the releif of the intention tremor of multiple sclerosis</TI>
<SO>British Journal of Neurosurgery</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>6</NO>
<PG>559-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duquette-1985" MODIFIED="2008-08-29 12:25:39 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Duquette 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-08-29 12:25:39 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duquette P, Pleines J, du Souich P</AU>
<TI>Isoniazid for tremor in multiple sclerosis: a controlled trial</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>12</NO>
<PG>1772-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feys-2004" MODIFIED="2008-08-29 12:26:07 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Feys 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-29 12:26:07 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feys P, Helsen W, Liu X, Mooren D, Albrecht H, Nuttin B et al</AU>
<TI>Effects of peripheral cooling on intention tremor in multiple sclerosis</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>2004</YR>
<VL>76</VL>
<NO>3</NO>
<PG>373-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francis-1986" MODIFIED="2008-08-29 12:26:26 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Francis 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-08-29 12:26:26 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francis DA, Grundy D, Heron JR</AU>
<TI>The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1986</YR>
<VL>49</VL>
<NO>1</NO>
<PG>87-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuller-1996" MODIFIED="2008-08-29 12:26:49 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Fuller 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-29 12:26:49 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuller KJ, Dawson K, Wiles CM</AU>
<TI>Physiotherapy in chronic multiple sclerosis: a controlled trial</TI>
<SO>Clinical Rehabilitation</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>195-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gbadamosi-2001" MODIFIED="2008-09-01 09:27:01 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Gbadamosi 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-01 09:27:01 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gbadamosi J, Buhmann C, Moench A, Heesen C</AU>
<TI>Failure of ondansetron in treating cerebellar tremor in MS patients-an open label pilot study</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>5</NO>
<PG>308-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geny-1996" MODIFIED="2008-08-29 12:27:28 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Geny 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-29 12:27:28 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geny C, Nguyen JP, Pollin B, Feve A, Ricolfi F, Cesaro P et al</AU>
<TI>Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation</TI>
<SO>Movement Disorders</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>5</NO>
<PG>489-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldman-1992" MODIFIED="2008-08-29 12:27:44 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Goldman 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-08-29 12:27:44 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldman MS, Kelly PJ</AU>
<TI>Symptomatic and functional outcome of stereotactic ventralis lateralis thalamotomy for intention tremor</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1992</YR>
<VL>77</VL>
<NO>2</NO>
<PG>223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hooper-2002" MODIFIED="2008-08-29 12:28:09 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Hooper 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-29 12:28:09 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hooper J, Taylor R, Pentland B, Whittle IR</AU>
<TI>A prospective study of thalamic deep brain stimulation for the treatment of movement disorders in multiple sclerosis</TI>
<SO>British Journal of Neurosurgery</SO>
<YR>1992</YR>
<VL>77</VL>
<NO>2</NO>
<PG>223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jobst-1989" MODIFIED="2008-08-29 12:28:28 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Jobst 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-08-29 12:28:28 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jobst U</AU>
<TI>Posturographic biofeedback training in equilibrium disorders</TI>
<SO>Fortschritte der Neurologie Psychiatrie</SO>
<YR>1989</YR>
<VL>57</VL>
<NO>2</NO>
<PG>74-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1996" MODIFIED="2008-08-29 12:28:44 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Jones 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-29 12:28:44 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones L, Lewis Y, Harrison J, Wiles CM</AU>
<TI>The effectiveness of occupational therapy and physiotherapy in multiple sclerosis patients with ataxia of the upper limb and trunk</TI>
<SO>Clinical Rehabilitation</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>277-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koller-1984a" MODIFIED="2008-08-29 12:29:06 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Koller 1984a" YEAR="1984">
<REFERENCE MODIFIED="2008-08-29 12:29:06 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koller WC, Biary N</AU>
<TI>Effect of alcohol on tremors: comparison with propranolol</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>2</NO>
<PG>221-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koller-1984b" MODIFIED="2008-08-29 12:29:14 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Koller 1984b" YEAR="1984">
<REFERENCE MODIFIED="2008-08-29 12:29:14 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koller WC</AU>
<TI>Pharmacologic trials in the treatment of cerebellar tremor</TI>
<SO>Archives of Neurology</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>3</NO>
<PG>280-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemster-1994" MODIFIED="2008-08-29 12:29:41 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Lemster 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-08-29 12:29:41 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemster B, Huang LL, Irish W, Woo J, Carroll PB, Abu-Elmagd K et al</AU>
<TI>Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial</TI>
<SO>Autoimmunity</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>2</NO>
<PG>89-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-2001" MODIFIED="2008-08-29 12:30:05 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Matsumoto 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-29 12:30:05 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto J, Morrow D, Kaufman K, Davis D, Ahlskog JE, Walker A et al</AU>
<TI>Surgical therapy for tremor in multiple sclerosis: an evaluation of outcome measures</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>10</NO>
<PG>1876-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monaca_x002d_Charley-2003" MODIFIED="2008-08-29 12:30:26 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Monaca-Charley 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-29 12:30:26 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monaca-Charley C, Stojkovic T, Duhamel A, De Seze J, Ferriby D, Vermersch P</AU>
<TI>Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>2003</YR>
<VL>250</VL>
<NO>10</NO>
<PG>1190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montgomery-1999" MODIFIED="2008-08-29 12:30:50 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Montgomery 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-29 12:30:50 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery EB Jr, Baker KB, Kinkel RP, Barnett G</AU>
<TI>Chronic thalamic stimulation for the tremor of multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>3</NO>
<PG>625-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-1975" NAME="Morgan 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan M.H., Hewer R.L., Cooper R</AU>
<TI>'Application of an objective method of assessing intention tremor-a further study on the use of weights to reduce intention tremor'</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1975</YR>
<VL>38</VL>
<NO>3</NO>
<PG>259-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrow-1985" MODIFIED="2008-08-29 12:31:36 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Morrow 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-08-29 12:31:36 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrow J, McDowell H, Ritchie C, Patterson V</AU>
<TI>Isoniazid and action tremor in multiple sclerosis</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1985</YR>
<VL>48</VL>
<NO>3</NO>
<PG>282-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nandi-2004" MODIFIED="2008-08-29 12:31:53 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Nandi 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-29 12:31:52 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nandi D, Aziz TZ</AU>
<TI>Deep brain stimulation in the management of neuropathic pain and multiple sclerosis tremor</TI>
<SO>Journal of Clinical Neurophysiology</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>1</NO>
<PG>31-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niranjan-2000" MODIFIED="2008-08-29 12:32:09 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Niranjan 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-08-29 12:32:09 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niranjan A, Kondziolka D, Baser S, Heyman R, Lunsford LD</AU>
<TI>Functional outcomes after gamma knife thalamotomy for essential tremor and MS-related tremor</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>3</NO>
<PG>443-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quintern-1999a" MODIFIED="2008-08-29 12:32:33 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Quintern 1999a" YEAR="1999">
<REFERENCE MODIFIED="2008-08-29 12:32:33 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quintern J, Immisch I, Albrecht H, Pollmann W, Glasauer S, Straube A</AU>
<TI>Influence of visual and proprioceptive afferences on upper limb ataxia in patients with multiple sclerosis</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1999</YR>
<VL>163</VL>
<NO>1</NO>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rice-1997" MODIFIED="2008-08-29 12:33:01 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Rice 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-08-29 12:33:01 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC</AU>
<TI>Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1997</YR>
<VL>62</VL>
<NO>3</NO>
<PG>282-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabra-1982" MODIFIED="2008-08-29 12:33:17 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Sabra 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-08-29 12:33:17 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabra AF, Hallett M, Sudarsky L, Mullally W</AU>
<TI>Treatment of action tremor in multiple sclerosis with isoniazid</TI>
<SO>Neurology</SO>
<YR>1982</YR>
<VL>32</VL>
<NO>8</NO>
<PG>912-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samra-1970" MODIFIED="2008-08-29 12:34:02 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Samra 1970" YEAR="1970">
<REFERENCE MODIFIED="2008-08-29 12:34:02 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samra K, Waltz JM, Riklan M, Koslow M, Cooper IS</AU>
<TI>Relief of intention tremor by thalamic surgery</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1970</YR>
<VL>33</VL>
<NO>1</NO>
<PG>7-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheinberg-1984" MODIFIED="2008-08-29 12:34:17 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Scheinberg 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-08-29 12:34:17 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheinberg L, Gesser BS</AU>
<TI>INH in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>134</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schimrigh-2001" MODIFIED="2008-08-29 12:34:31 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Schimrigh 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-29 12:34:31 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schimrigh S, Lukas C, Hoffmann V, Hellwig K</AU>
<TI>Budipine is effective in treatment of intentional tremor in multiple sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>2001</YR>
<VL>248</VL>
<PG>176</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulder-1999" MODIFIED="2008-08-29 12:34:43 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Schulder 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-29 12:34:43 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulder M, Sernes TJ, Karimi R</AU>
<TI>Thalamic stimulation in patients with multiple sclerosis: long-term follow up</TI>
<SO>Stereotactic Functional Neurosurgery</SO>
<YR>2003</YR>
<VL>80</VL>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sechi-1989" MODIFIED="2008-08-29 12:35:06 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Sechi 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-08-29 12:35:06 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sechi GP, Zuddas M, Pireda M, Agnetti V, Sau G, Piras ML et al</AU>
<TI>Treatment of cerebellar tremors with carbemazepine: a controlled trial with long term follow up</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39</VL>
<NO>8</NO>
<PG>1113-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sechi-2003" MODIFIED="2008-08-29 12:35:57 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Sechi 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-29 12:35:57 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sechi G, Agnetti V, Sulas FM, Sau G, Corda D, Pitzolu MG et al</AU>
<TI>Effects of topiramate in patients withh cerebellar tremor</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1023-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shahzadi-1995" MODIFIED="2008-08-29 12:36:17 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Shahzadi 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-08-29 12:36:17 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shahzadi S, Tasker RR, Lozano A</AU>
<TI>Thalamotomy for essential and cerebellar tremor</TI>
<SO>Stereotactic Functional Neurosurgery</SO>
<YR>1995</YR>
<VL>65</VL>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solaris-1999" MODIFIED="2008-08-29 12:36:43 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Solaris 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-29 12:36:43 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solaris A, Filippini G, Gasco P, Colla L, Salmaggi A, La Mantia L et al</AU>
<TI>Physical rehabilitation has a positive effect on disability in multiple sclerosis patients</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Speelman-1984" MODIFIED="2008-08-29 12:37:01 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Speelman 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-08-29 12:37:01 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speelman JD, Van Manen J</AU>
<TI>Sterotactic thalamotomy for the releif of intention tremor of multiple sclerosis</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1984</YR>
<VL>47</VL>
<NO>6</NO>
<PG>596-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Striano-2006" MODIFIED="2008-08-29 12:37:24 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Striano 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-29 12:37:24 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Striano P, Coppola A, Vacca G, Zara F, Bresica Morra V, Orefice G et al</AU>
<TI>Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerabilty and efficacy study</TI>
<SO>Journal of Neurology</SO>
<YR>2006</YR>
<VL>253</VL>
<NO>6</NO>
<PG>762-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taha-1999" MODIFIED="2008-08-29 12:37:40 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Taha 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-29 12:37:40 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taha JM, Janszen MA, Favre J</AU>
<TI>Thalamic deep brain stimulation for the treatment of head, voice, and bilateral limb tremor</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>1</NO>
<PG>68-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waubabt-2001" MODIFIED="2008-08-29 12:38:13 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Waubabt 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-29 12:38:13 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Waubant E, Hosseini H, N'guyen JP, Jedynak CP, Welter ML, Apartis E et al</AU>
<TI>Efficacy of thalamic stimulation in multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>2001</YR>
<VL>7</VL>
<PG>S29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zajicek-2003" MODIFIED="2008-08-29 12:38:44 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Zajicek 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-29 12:38:44 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al</AU>
<TI>Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised palcebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9395</NO>
<PG>1517-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zajicek-2005" MODIFIED="2008-08-29 12:39:20 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Zajicek 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-29 12:39:20 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM et al</AU>
<TI>Cannabinoids iin multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>12</NO>
<PG>1664-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-29 12:50:26 +0200" MODIFIED_BY="Deirdre Beecher">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-29 12:50:26 +0200" MODIFIED_BY="Deirdre Beecher">
<REFERENCE ID="REF-Alusi-1999" MODIFIED="2008-08-29 12:40:40 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Alusi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Alusi SH, Glickman S, Aziz TZ, Bain PG</AU>
<TI>Tremor in multiple sclerosis</TI>
<SO>Journal of Neurolology Neurosurgery and Psychiatry</SO>
<YR>1999</YR>
<VL>66</VL>
<PG>131-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alusi-2001a" MODIFIED="2008-08-29 12:44:01 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Alusi 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Alusi SH, Worthington J, Glickman S, Bain PG</AU>
<TI>A study of tremor in multiple sclerosis</TI>
<SO>Brain</SO>
<YR>2001</YR>
<VL>124</VL>
<PG>720-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alusi-2003" MODIFIED="2008-08-29 12:44:18 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Alusi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Alusi SH, Glickman S, Patel N, Worthington J, Bain PG</AU>
<TI>Target board test for the quantification of ataxia in tremulous patients</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>2</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ashworth-1964" MODIFIED="2008-08-29 12:44:25 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Ashworth 1964" TYPE="JOURNAL_ARTICLE">
<AU>Ashworth B</AU>
<TI>Preliminary trial of carisoprodol in multiple sclerosis</TI>
<SO>Practitioner</SO>
<YR>1964</YR>
<VL>192</VL>
<PG>540-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2003" MODIFIED="2008-08-29 12:47:04 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Clarke 2003" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.0 [updated March 2003]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<PB>Oxford: Update Software</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erasmus-2001" MODIFIED="2008-08-29 12:47:41 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Erasmus 2001" TYPE="JOURNAL_ARTICLE">
<AU>Erasmus LP, Sarno S, Albrecht H, Schwecht M, Pollmann W, Konig N</AU>
<TI>Measurement of ataxic symptoms with a graphics tablet: standard values in controls and validity in multiple sclerosis patients</TI>
<SO>Journal of Neuroscience Methods</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>1</NO>
<PG>25-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fahn-1988" MODIFIED="2008-08-29 12:47:51 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Fahn 1988" TYPE="BOOK_SECTION">
<AU>Fahn S, Tolosa E, Marin C</AU>
<TI>Clinical rating scale for tremor</TI>
<SO>Parkinson&#8217;s disease and movement disorders</SO>
<YR>1988</YR>
<PG>225-34</PG>
<PB>Urban and Schwarzenberg</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghez-2000" MODIFIED="2008-08-29 12:48:40 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Ghez 2000" TYPE="BOOK_SECTION">
<AU>Ghez C, Thach WT</AU>
<TI>The cerebellum</TI>
<SO>Principles of Neural Science</SO>
<YR>2000</YR>
<EN>4th</EN>
<PB>McGraw Hill</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hickman-2001" MODIFIED="2008-08-29 12:49:38 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Hickman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hickman SJ, Brierley CM, Silver NC, Moseley IF, Scolding NJ, Compston DA, et al</AU>
<TI>Infratentorial hypointense lesion volume on T1-weighted magnetic resonance imaging correlates with disability in patients with chronic cerebellar ataxia due to multiple sclerosis</TI>
<SO>Journal of Neurological Science</SO>
<YR>2001</YR>
<VL>187</VL>
<NO>1-2</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hooper-1998" MODIFIED="2008-08-29 12:49:59 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Hooper 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hooper J, Taylor R, Pentland B, Whittle IR</AU>
<TI>Rater reliability of Fahn's tremor rating scale in patients with multiple sclerosis</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>9</NO>
<PG>1076-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurtzke-1983" MODIFIED="2008-08-29 12:50:08 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Kurtzke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzke JF</AU>
<TI>Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<PG>1444-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2001" MODIFIED="2008-08-29 12:50:26 +0200" MODIFIED_BY="Deirdre Beecher" NAME="McDonald 2001" TYPE="JOURNAL_ARTICLE">
<AU>McDonald WI, Compston A, Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al</AU>
<TI>'Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis'</TI>
<SO>Annals of Neurolology</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>1</NO>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1999" NAME="Murray 1999" TYPE="CONFERENCE_PROC">
<AU>Murray I.A., Johnson G.R</AU>
<TI>'Upper limb kinematics and dynamics: the development and validation of a measurement technique'</TI>
<SO>Measurement and simulations in musculoskeletal biomechanics meeting, UK</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poser-1983" NAME="Poser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C</AU>
<TI>'New diagnostic criteria for multiple sclerosis: guidelines for research protocols'</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quintern-1999" NAME="Quintern 1999" TYPE="JOURNAL_ARTICLE">
<AU>Quintern J., Immisch I., Albrecht H., Pollmann W., Glasauer S., Straube A</AU>
<TI>'Influence of visual and proprioceptive afferences on upper limb ataxia in patients with multiple sclerosis'</TI>
<SO>Journal of Neurological Science</SO>
<YR>1999</YR>
<VL>163</VL>
<NO>1</NO>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudick-2002" NAME="Rudick 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rudick R.A., Cutter G, Reingold S</AU>
<TI>'The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials'</TI>
<SO>Multiple Sclerosis</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>5</NO>
<PG>359-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1990" NAME="Simpson 1990" TYPE="BOOK">
<AU>Simpson J., (editor)</AU>
<SO>Oxford English Dictionary</SO>
<YR>1990</YR>
<EN>3rd</EN>
<PB>OUP</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swingler-1992" NAME="Swingler 1992" TYPE="JOURNAL_ARTICLE">
<AU>Swingler R.J., Compston D.A</AU>
<TI>'The morbidity of multiple sclerosis'</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1992</YR>
<VL>83</VL>
<PG>325-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiles-2003" NAME="Wiles 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wiles C.M., Newcombe R.G., Fuller K.J., Jones A., Price M</AU>
<TI>'Use of videotape to assess mobility in a controlled randomized crossover trial of physiotherapy in chronic multiple sclerosis'</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>3</NO>
<PG>256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Armutlu-2001">
<CHAR_METHODS>
<P>parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>26 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>physiotherapy plus Johnstone pressure splint vs. physiotherapy alone (4 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>objective measures of gait and equilibrium testing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>assessor only blinding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bozek-1987">
<CHAR_METHODS>
<P>crossover</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>isoniazid vs placebo ( 4 weeks each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>videotaped assessment of tremor, accelerometry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fox-2004">
<CHAR_METHODS>
<P>crossover</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>14 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>oral Cannador vs placebo (2 weeks each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>tremor index, accelerometry, ataxia scale, spiral draw, finger tap, 9HPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hallett-1985">
<CHAR_METHODS>
<P>crossover</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>7 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>isoniazid vs. placebo (4 weeks each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>videotaped assessment of tremor, accelerometry, self rating of improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Killestein-2002">
<CHAR_METHODS>
<P>twofold crossover</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>dronabinol vs. cannabis sativa plant extract vs. placebo (4 weeks each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>9HPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lord-1998">
<CHAR_METHODS>
<P>parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>23 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Facilitation vs. task orientated physiotherapy (5-7 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Berg balance test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>assessor only blinding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Orsnes-2000">
<CHAR_METHODS>
<P>crossover</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>14 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>baclofen vs. placebo (18 days each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>forceplate measurements</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schuurman-2000">
<CHAR_METHODS>
<P>parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 MS patients (68 patients with tremor in total)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>thalamic stimulation vs. thalamotomy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>videotaped assessment of tremor, modified tremor scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>assessor only blinding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wade-2004">
<CHAR_METHODS>
<P>parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>13 MS patients with tremor (160 MS patients in total)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>sublingual Sativex vs. placebo (10 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>VAS, tremor ADL questionnaire, 9HPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wiles-2001">
<CHAR_METHODS>
<P>twofold crossover</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>39 MS patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>home physiotherapy vs hospital physiotherapy vs. no treatment (8 weeks each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>single leg balance time, 9HPT, videotaped clinical assessment of gait</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>assessor only blinding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>outcomes refer to primary measures of ataxia or tremor only</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aisen-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alusi-2001b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bakhos-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>High risk of bias</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benabid-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berk-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bittar-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brice-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cardini-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Assessor unblinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Critchley-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duquette-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feys-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Francis-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fuller-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Assessor unblinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gbadamosi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Geny-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldman-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hooper-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jobst-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Assessor unblinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koller-1984a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract separate MS data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koller-1984b">
<CHAR_REASON_FOR_EXCLUSION>
<P>study methods not clear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lemster-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract separate tremor/ataxia data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matsumoto-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monaca_x002d_Charley-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment duration less than one week</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Montgomery-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morgan-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Assessor unblinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morrow-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nandi-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niranjan-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quintern-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rice-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment duration less than one week</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sabra-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Samra-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scheinberg-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schimrigh-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schulder-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sechi-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Assessor unblinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sechi-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shahzadi-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Solaris-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract separate tremor/ataxia data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Speelman-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Striano-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taha-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waubabt-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zajicek-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>High risk of bias for ataxia outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zajicek-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>High risk of bias for ataxia outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Armutlu-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bozek-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fox-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hallett-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killestein-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lord-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Orsnes-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schuurman-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wade-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wiles-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Meta analysis was not performed.</NAME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-18 13:31:44 +0200" MODIFIED_BY="Deirdre Beecher">
<APPENDIX ID="APP-01" MODIFIED="2008-09-18 13:31:44 +0200" MODIFIED_BY="Deirdre Beecher" NO="1">
<TITLE MODIFIED="2008-09-01 09:22:05 +0200" MODIFIED_BY="Deirdre Beecher">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-18 13:31:44 +0200" MODIFIED_BY="Deirdre Beecher">
<P>1. Multiple sclerosis<BR/>2. Multiple-sclerosis*:me<BR/>3. 1 or 2<BR/>4. Demyelinating Disease<BR/>5. Demyelinating Diseases<BR/>6. Demyelinating-Diseases*:me<BR/>7. 4 or 5 or 6<BR/>8. Transverse Myelitis<BR/>9. Myelitis-Transverse*:me<BR/>10. 8 or 9<BR/>11. Neuromyelitis Optica<BR/>12. Neuromyelitis-Optica*:me<BR/>13. 11 or 12<BR/>14. Optic Neuritis<BR/>15. Optic-Neuritis*:me<BR/>16. 14 or 15<BR/>17. Encephalomyelitis Acute Disseminated<BR/>18. Encephalomyelitis-Acute-Disseminated*:me<BR/>19. 17 or 18<BR/>20. Adem<BR/>21. Devic<BR/>22. 3 or 7 or 10 or 13 or 16 or 19 or 20 or 21<BR/>23."ataxia" [tw]<BR/>24. "tremor"[tw]<BR/>25. ATAXIA explode all trees [MESH]<BR/>26. TREMOR explode all trees [MeSH]<BR/>27. 23 OR 22<BR/>28. 22 AND 27</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-09-18 13:28:34 +0200" MODIFIED_BY="Deirdre Beecher" NO="2">
<TITLE MODIFIED="2008-09-01 09:22:24 +0200" MODIFIED_BY="Deirdre Beecher">MEDLINE (PubMed) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-18 13:28:34 +0200" MODIFIED_BY="Deirdre Beecher">
<P>1.Multiple Sclerosis[MESH]<BR/>2.Myelitis, Transverse[MESH:noexp]<BR/>3.Demyelinating Diseases[MESH:noexp]<BR/>4.Encephalomyelitis, Acute Disseminated[MESH]<BR/>5."multiple sclerosis" OR "transverse myelitis" OR "optic neuritis" OR device OR adem OR "neuromyelitis optica" Field: Title/Abstract<BR/>6.#1 OR #2 OR #3 OR #4 OR #5<BR/>7."Clinical Trial"[Publication Type]<BR/>8.randomized Field: Title/Abstract<BR/>9.placebo Field: Title/Abstract<BR/>10."drug therapy"[Subheading]<BR/>11.randomly Field: Title/Abstract<BR/>12.trial Field: Title/Abstract<BR/>13.groups Field: Title/Abstract<BR/>14.#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13<BR/>15.#6 AND #14<BR/>16."Animals"[MeSH]<BR/>17."Humans"[MeSH]<BR/>18. #16 NOT (#16 AND #17)<BR/>19.#15 NOT #18<BR/>20 "ataxia"[tw]<BR/>21."tremor"[tw]<BR/>22 ATAXIA explode all tress [MESH]<BR/>23. TREMOR explode all trees [MeSH]<BR/>24. 20 OR 24<BR/>25. 19 AND 24</P>
<P>
<B>
<BR/>
</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-09-18 13:29:03 +0200" MODIFIED_BY="Deirdre Beecher" NO="3">
<TITLE MODIFIED="2008-09-01 09:22:37 +0200" MODIFIED_BY="Deirdre Beecher">EMBASE (EMBASE.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-18 13:29:03 +0200" MODIFIED_BY="Deirdre Beecher">
<P>1'encephalomyelitis'/exp<BR/>2 'demyelinating disease'/exp<BR/>3 'multiple sclerosis'/exp<BR/>4 'myelooptic neuropathy'/exp<BR/>5 'multiple sclerosis':ti,ab<BR/>6: neuromyelitis optica:ti,ab<BR/>7. enecephalomyelitis:ti,ab<BR/>8. adem:ti,ab<BR/>9 .devic:ti,ab<BR/>10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9<BR/>11. 'crossover procedure'/exp<BR/>12. 'double blind procedure'/exp<BR/>13. 'single blind procedure'/exp<BR/>14. 'randomized controlled trial'/exp<BR/>15.random*:ti,ab<BR/>16.factorial*:ti,ab<BR/>17. crossover:ti,ab<BR/>18.cross AND over:ti,ab<BR/>19. placebo*:ti,ab<BR/>20. 'double blind':ti,ab<BR/>21.'single blind':ti,ab<BR/>22. assign*:ti,ab<BR/>23.alloact*:ti,ab<BR/>24. volunteer*:ti,ab<BR/>25.11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24<BR/>26.10 and 25<BR/>27. 26 and human<BR/>28. "ataxia"[MESH<BR/>29. "tremor" [tw]<BR/>30. ATAXIA explode all tress [MESH]<BR/>31. TREMOR explode all trees [MeSH]<BR/>32. 28 OR 31<BR/>33. 27 AND 32</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>